1.Development and application of a new digital electric fire needle instrument.
Meng-Ru HE ; Xin HUI ; Bai-Xiao ZHAO ; Ze-Lin CHEN
Chinese Acupuncture & Moxibustion 2023;43(5):593-596
		                        		
		                        			
		                        			In view of the limitations of the high operational difficulty, safety hazards and adverse reactions of traditional fire needle, and unclear treatment parameters of existing electric fire needles, a new digital electric fire needle instrument was designed and developed in this study. This instrument is a gun type structure, consisting of a gun body, a power supply interface on the gun body, a display unit and a drive unit, a heating unit, a cooling unit, a positioning unit, and a needle inserting unit in the gun body. This instrument can digitally realize the regulation of parameters such as fire needle inserting temperature, depth and speed, and it has the advantageous features of intelligent needle burning, precise positioning, and safe and easy operation. This instrument meets the needs of more patients, medical professionals and scientific researchers, and is conducive to promoting the development of fire needle acupuncture therapy.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Needles
		                        			;
		                        		
		                        			Heating
		                        			;
		                        		
		                        			Research Personnel
		                        			;
		                        		
		                        			Temperature
		                        			
		                        		
		                        	
2.Association between fasting plasma glucose and mild cognitive impairment in Chinese 55 and older population from four provinces.
Xiao Fang JIA ; Zhi Hong WANG ; Fei Fei HUANG ; Wen Wen DU ; Hong Ru JIANG ; Chang SU ; Xiao Feng ZHANG ; Jing BAI ; Bing ZHANG ; Hui Jun WANG
Chinese Journal of Epidemiology 2022;43(10):1590-1595
		                        		
		                        			
		                        			Objective: To analyze the association of fasting plasma glucose (FPG) with mild cognitive impairment (MCI) in the Chinese middle-aged and elderly population from four provinces. Methods: Data were drawn from the baseline data of the Community-based Cohort Study on Nervous System Disease 2018-2019. We selected 3 272 subjects aged 55 and above with completed information on demographics, lifestyle, disease history, cognitive test, psychological assessment, and bio-chemistries measurement, and who were capable of performing basic activities of daily living but without Alzheimer's disease during recruitment. A multivariate logistic regression model was employed to analyze the association between FPG and MCI. Results: Median level of FPG in the study population was 5.5 mmol/L. The prevalence of MCI was 24.8%, and those in groups of the FPG quintile were 19.4%, 22.2%, 29.2%, 26.6%, and 26.1%, respectively, which significantly increased the trend (P=0.002). After adjustment of confounders, multivariate logistic regression analysis found that the MCI risk of subjects in the Q3,Q4 and Q5 groups was 1.641 (95%CI: 1.226-2.131), 1.373 (95%CI: 1.036-1.825), 1.402 (95%CI: 1.054-1.871) times as high as that in the Q1 group, respectively. Conclusion: High FPG level might serve as a risk factor for MCI in the middle-aged and elderly population, suggesting the importance of monitoring and controlling plasma glucose even without diabetes.
		                        		
		                        		
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Fasting
		                        			;
		                        		
		                        			Blood Glucose
		                        			;
		                        		
		                        			Activities of Daily Living
		                        			;
		                        		
		                        			Cohort Studies
		                        			;
		                        		
		                        			Cognitive Dysfunction/epidemiology*
		                        			;
		                        		
		                        			China/epidemiology*
		                        			
		                        		
		                        	
3.Regulatory effect of dietary nutrients on the pathogenesis of Alzheimer's disease
Yu-xiao SHEN ; Ya-ru BAI ; Ya-fei SHI ; Hao WANG ; Yong-juan XIN
Journal of Public Health and Preventive Medicine 2022;33(6):1-5
		                        		
		                        			
		                        			Alzheimer's disease (AD), also known as dementia , is a progressive neurodegenerative disease. The main clinical manifestations of AD patients are memory loss, cognitive dysfunction, abnormal behavior and social impairment . At present , there is no effective treatment available for AD, so early prevention and control is particularly important. Since ancient times, the theory of “medicine and food are of the same origin” has existed in traditional Chinese medicine, therefore, a variety of food supplements have been used in the intervention and control of the progress of various diseases. Reasonable diet plays an important role in the early prevention and control of AD. This paper mainly reviews the effects of common plant polyphenols, vitamins, and fatty acids on the pathogenesis of AD, in order to clarify the role of dietary nutrients in the early prevention and control of AD, and to provide theoretical support for adjusting the dietary structure to improve brain health.
		                        		
		                        		
		                        		
		                        	
4.Epidemiological characteristics of COVID-19 epidemic in Ejina banner, Inner Mongolia Autonomous Region, October 2021.
Hui LI ; Wen Rui WANG ; Meng Guang FAN ; Bo Xi LIU ; Xiao Feng JIANG ; Xiao Ling TIAN ; Yun Feng XI ; Ru Yu BAI ; Fu Li CHI ; Sheng Mei YANG
Chinese Journal of Epidemiology 2022;43(2):189-194
		                        		
		                        			
		                        			Objective: To understand the epidemiological characteristics of COVID-19 epidemic in Ejina banner, Inner Mongolia, in October 2021 and provide evidence for the improvement of COVID-19 prevention and control. Methods: The information about the time, area and population distributions of COVID-19 cases in Ejina before November 13, 2021 and the gene sequencing result of the isolates were collected for a statistical descriptive analysis. Results: The first COVID-19 case in Ejina occurred on 7 October, 2021. A total of 164 COVID-19 cases were reported from October 19 to November 12. Most cases were distributed in 6 communities in Darahub (156 cases, 95.12%). The result of full gene sequencing of the isolates indicted that the pathogen was Delta variant (B.1.617.2). The male to female ratio of the cases was 1.3∶1. The age of cases ranged from 1 to 85 years, and the cases aged 20-59 years accounted for 78.66%. The main clinical symptoms were sore throat (91 cases, 91.92%), cough (49 cases, 49.49%) and fever (23 cases, 23.23%). Most cases were ordinary ones (81 cases, 49.39%) and mild ones (68 cases, 41.46%). The cases were mainly detected at the isolation points (84 cases, 51.22%) and through population based nucleic acid testing (62 cases, 37.80%). The basic reproduction number (R0) of COVID-19 was 5.3, the average incubation period was 3.9 days. The local government rapidly started Ⅳ level emergency response and conducted 10 rounds of nucleic acid tests. The transferring of travelers reduced the risk for the further spread of COVID-19 in Ejina. Conclusions: The epidemic of COVID-19 in Ejina characterized by strong transmission, short incubation period, herd susceptibility and case clustering. Delta variant (B.1.617.2) was the pathogen, which might be imported from Zeke port. Comprehensive prevention and control measures, such as closed-loop management and vaccination, should be continued. The successful transferring of the patients and travelers provided evidence for the effective and precise prevention and control of COVID-19 in a routine manner.
		                        		
		                        		
		                        		
		                        			Adolescent
		                        			;
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Aged, 80 and over
		                        			;
		                        		
		                        			COVID-19
		                        			;
		                        		
		                        			Child
		                        			;
		                        		
		                        			Child, Preschool
		                        			;
		                        		
		                        			China/epidemiology*
		                        			;
		                        		
		                        			Epidemics
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Infant
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			SARS-CoV-2
		                        			;
		                        		
		                        			Young Adult
		                        			
		                        		
		                        	
5.Experimental Study on the Protective Effect of Shenqi Zhilong Decoction Combined with Tripterygium Polygly- coside Tablets on Membranous Nephropathy Model Rats
Piliang XUE ; Liqi LI ; Xinxin LIU ; Ru BAI ; Hongbin XIAO ; Wenying NIU
China Pharmacy 2020;31(13):1575-1583
		                        		
		                        			
		                        			OBJECTIVE:To investigate the protective effect an d possible m echanism of Shenqi zhilong decoction (SZD) combined with Tripterygium polyglycoside tablets (TPT)on membranous nephropathy (MN)model rats. METHODS :MN rat model was established by subcutaneous and caudal vein injecting cationic bovine serum albumin + incomplete Freund adjuvant emulsion for 6 weeks. At the 3rd week of modeling ,model rats were randomly divided into model control group ,SZD low-dose and high-dose groups (4,8 g/kg,by total crude drugs ),TPT group (9 mg/kg),low-dose and high-dose of SZD+TPT groups (same dose as single group ),with 10 rats in each group  according to 24 h UTP and weight. Another 10 rats withoutmodeling were taken as blank control group. Blank control  group was given equal amount of water intragastrically  administration groups were given relevant medicine intragastrically,once a day ,for consecutive 4 weeks. The 24 h UTP of rats were detected one day before the last administration;1 h after the la st administration ,blood routine 中indexes(WBC,RBC,PLT),liver func tion indexes (TP,ALB,AST,ALT),blood lipid indexes (TC,TG,HDL-C,LDL-C), the contents of glucose (GLU),urea nitrogen (BUN)and serum creatinine (Scr)were detected in each group. Uranyl acetate-lead citrate staining was used to observe ultrastructural changes of renal tissue. Immunohistochemical method was used to detect the protein expression of TGF-β1 and HPA- 1 in renal tissue. RESULTS :Compared with blank control group ,in the model control group,the glomerular podocytes were widely fused or disappeared ,microvilli were formed ,basement membrane was heavily thickened,a large number of electron dense substance was deposited under the epithelium ,TGF-β1 and HPA- 1 positive cells were significantly increased ;24 h UTP ,PLT,the contents of TC ,TG and HDL-C ,the percentage of TGF-β1 and HPA- 1 positive cells were increased significantly ,while RBC ,the contents of TP and ALB were decreased significantly (P<0.05 or P<0.01). Compared with model control group ,above ultrastructural changes of administration groups were improved to different extents ,and TGF-β1 and HPA- 1 positive cells were decreased. The 24 h UTP ,the percentage of TGF-β1 positive cells (except for SZD low-dose group),WBC(except for SZD alone groups and combination groups ),PLT and TC content (except for TPT group ),TG content (except for SZD low-dose alone and its combination group ),the percentage of HPA- 1 positive cells were decreased significantly ; the percentage of TGF-β1 positive cells in SZD high-dose+TPT group as well as the percentage of HPA- 1 positive cells in SZD+TPT groups were significantly lower than TPT group. RBC and GLU content (except for SZD low-dose group and TPT group ),TP and ALB content (except for SZD low-dose group )were increased significantly ,while the content of GLU in SZD high-dose+TPT group was significantly higher than TPT tablets group (P<0.05 or P<0.01). CONCLUSIONS :SZD combined with TPT can relieve myelosuppression caused by TPT ,reduce proteinuria of MN model rats and improve pathological damage of renal tissue in rats. Its mechanism is related to the down-regulation of protein expression of TGF-β1 and HPA- 1,and the reduction of TC and TG content in the blood.
		                        		
		                        		
		                        		
		                        	
		                				6.Metabolism of a promising anti-tumor agent CAT3 in vitro 
		                			
		                			Sheng-yu ZHAO ; Ru-bing WANG ; Jie BAI ; Xiao-qing FAN ; Min-wan HU ; Yan-hong SUN ; Jin-ping HU ; Yan LI
Acta Pharmaceutica Sinica 2019;54(6):1108-1114
		                        		
		                        			
		                        			 CAT3 is a promising anti-brain tumor agent that has significant anti-tumor activity on Daoy or U87MG orthotopic xenograft in nude mice. This study was carried out to investigate the metabolic profiles of CAT3 in mouse/dog/human blood and microsome as well as in humanized recombinant enzymes. All animal care and experimental procedures were reviewed and approved by the Animal Ethics Committee of Chinese Academy of Medical Sciences. Our findings showed that CAT3 could be hydrolyzed to active metabolite PF403 by carboxylesterase, butyrylcholinesterase and serine hydrolase in mouse/dog/ human blood. PF403 could be further metabolized to M1 oxidative dehydration product, M2 double oxidation dehydration product, M3 methylation oxidative dehydration product, M4 oxidation product and M5 demethylation product, which were mainly catalyzed by CYP1A2, 1A1, 2C9 and 3A4, and slightly by CYP2B6, 2C8, 2C19 and 2D6. Besides oxidative metabolism, PF403 also was transformed into glucuronylation metabolites GLU-PF403 by Phase II enzymes UGT1A1, 1A3 and 1A9. Taken together, the metabolism of CAT3 was a multiple enzyme catalytic reaction. These results could provide valuable information for potential enzyme-mediated DDI in clinic studies. 
		                        		
		                        		
		                        		
		                        	
7. The clinical application of keystone design perforator flaps
Jiuzuo HUANG ; Nanze YU ; Xiao LONG ; Ru ZHAO ; Ming BAI ; Xiaojun WANG
Chinese Journal of Plastic Surgery 2018;34(9):720-723
		                        		
		                        			 Objective:
		                        			To introduce the experience in skin defect reconstruction with keystone design perforator flap.
		                        		
		                        			Methods:
		                        			From January 2012 to December 2012, 26 patients with different types of skin defect were repaired with keystone design perforator flaps, including 21 classic keystone design perforator flaps, 3 short incision keystone design perforator flaps, and 2 Omega variant keystone design perforator flaps.
		                        		
		                        			Results:
		                        			One patient suffered partial flap loss and healed secondarily. All other patients recovered smoothly without complications.
		                        		
		                        			Conclusions
		                        			Keystone design perforator flap offers a versatile technique for skin defect reconstruction except for scalp. 
		                        		
		                        		
		                        		
		                        	
8.Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study.
Jian-Qiu WU ; Yong-Ping SONG ; Li-Ping SU ; Ming-Zhi ZHANG ; Wei LI ; Yu HU ; Xiao-Hong ZHANG ; Yu-Huan GAO ; Zuo-Xing NIU ; Ru FENG ; Wei WANG ; Jie-Wen PENG ; Xiao-Lin LI ; Xue-Nong OUYANG ; Chang-Ping WU ; Wei-Jing ZHANG ; Yun ZENG ; Zhen XIAO ; Ying-Min LIANG ; Yong-Zhi ZHUANG ; Ji-Shi WANG ; Zi-Min SUN ; Hai BAI ; Tong-Jian CUI ; Ji-Feng FENG
Chinese Medical Journal 2018;131(15):1767-1775
		                        		
		                        			Background:
		                        			Prospective real-life data on the safety and effectiveness of rituximab in Chinese patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) are limited. This real-world study aimed to evaluate long-term safety and effectiveness outcomes of rituximab plus chemotherapy (R-chemo) as first-line treatment in Chinese patients with DLBCL or FL. Hepatitis B virus (HBV) reactivation management was also investigated.
		                        		
		                        			Methods:
		                        			A prospective, multicenter, single-arm, noninterventional study of previously untreated CD20-positive DLBCL or FL patients receiving first-line R-chemo treatment at 24 centers in China was conducted between January 17, 2011 and October 31, 2016. Enrolled patients underwent safety and effectiveness assessments after the last rituximab dose and were followed up for 3 years. Effectiveness endpoints included progression-free survival (PFS) and overall survival (OS). Safety endpoints were adverse events (AEs), serious AEs, drug-related AEs, and AEs of special interest. We also reported data on the incidence of HBV reactivation.
		                        		
		                        			Results:
		                        			In total, 283 previously untreated CD20-positive DLBCL and 31 FL patients from 24 centers were enrolled. Three-year PFS was 59% (95% confidence interval [CI]: 50-67%) for DLBCL patients and 46% (95% CI: 20-69%) for FL patients. For DLBCL patients, multivariate analyses showed that PFS was not associated with international prognostic index, tumor maximum diameter, HBV infection status, or number of rituximab treatment cycles, and OS was only associated with age >60 years (P < 0.05). R-chemo was well tolerated. The incidence of HBV reactivation in hepatitis B surface antigen (HBsAg)-positive and HBsAg-negative/hepatitis B core antibody-positive patients was 13% (3/24) and 4% (3/69), respectively.
		                        		
		                        			Conclusions:
		                        			R-chemo is effective and safe in real-world clinical practice as first-line treatment for DLBCL and FL in China, and that HBV reactivation during R-chemo is manageable with preventive measures and treatment.
		                        		
		                        			Trial Registration
		                        			ClinicalTrials.gov, NCT01340443; https://clinicaltrials.gov/ct2/show/NCT01340443.
		                        		
		                        		
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Aged, 80 and over
		                        			;
		                        		
		                        			Antineoplastic Combined Chemotherapy Protocols
		                        			;
		                        		
		                        			therapeutic use
		                        			;
		                        		
		                        			China
		                        			;
		                        		
		                        			Cyclophosphamide
		                        			;
		                        		
		                        			administration & dosage
		                        			;
		                        		
		                        			Doxorubicin
		                        			;
		                        		
		                        			administration & dosage
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Follow-Up Studies
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Lymphoma, Follicular
		                        			;
		                        		
		                        			drug therapy
		                        			;
		                        		
		                        			Lymphoma, Large B-Cell, Diffuse
		                        			;
		                        		
		                        			drug therapy
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Prospective Studies
		                        			;
		                        		
		                        			Rituximab
		                        			;
		                        		
		                        			therapeutic use
		                        			;
		                        		
		                        			Vincristine
		                        			;
		                        		
		                        			administration & dosage
		                        			
		                        		
		                        	
9.Isolation and identification of exosomes derived from bone marrow mesenchymal stem cells
Ru-Ling WANG ; Xiao-Feng WEI ; Kuo QI ; Li-Ming WANG ; Ying LI ; Zhong-Tian BAI ; Xiang YAN
Basic & Clinical Medicine 2018;38(5):649-653
		                        		
		                        			
		                        			Objective To develop a method of isolation and identification of exosomes of bone marrow mesenchymal stem cells.Methods The mesenchymal stem cells were cultured by whole bone marrow adherence method.A new reagent -exosomes extraction kit was used to isolate and collecte exosomes.The exosomes were identified by elec-tron microscopy,particle size detection,flow cytometry and Western blot.Results The expression of CD45 on the surface of the third generation bone marrow mesenchymal stem cells was negative,and CD73 and CD105 were posi-tive;exosomes derived from bone marrow mesenchymal stem cells were round or oval,the size is non-uniform,the diameter is 30~100 nm,have a complete membrane structure,and containing low-density substances;Particle size detection particle diameter of the main peak was 61.25 nm, in which the diameter of particles was about 20-200 nm accounted for 72.4%;exosome expressed CD63 and CD81;The expression of CD9 and CD63 from cell cul-ture supernatants was positive.Conclusions The exosomes can be collected in the medium of mesenchymal stem cells.The exosomes derived from bone marrow mesenchymal stem cells can be identified by electron microscopy, particle size detection,flow cytometry and Western blot.
		                        		
		                        		
		                        		
		                        	
10.Efficacy analysis on hip replacement for hip-joint diseases with Parkinson disease.
Qi-Cai SUN ; Xuan-Liang RU ; Yan-Fei XIA ; Xiao-Li LIU ; Bai-Shan SONG ; Song QIAO ; Shi-Gui YAN ; Xiang-Hua WANG
China Journal of Orthopaedics and Traumatology 2017;30(12):1102-1106
OBJECTIVETo explore clinical efficacy of hip replacement for hip-joint diseases with Parkinson disease.
METHODSFrom December 2011 to December 2016, 18 patients with hip-joint diseases with Parkinson disease treated by hip replacement, including 8 males and 10 females aged from 59 to 87 years old with an average of 71 years old. Among them, 3 cases were developmental dysplasia of hip, 3 cases were femoral head necrosis and 12 cases were femoral neck fracture. All patients manifested with obvious pain and limitation of stepping ability. Postoperative complications were observed and Harris score were used to compare hip joint function after operation.
RESULTSThe incision were healed well, and pain were alleviated or disappeared, and hip joint function were improved. Eighteen patients were followed up from 1 to 3 years with an average of 2.3 years. At the latest follow up, 14 cases recovered freedom-walk, 2 cases could walk with walking stick, 1 case could walk with walking aid and 1 case was died. Among 18 patients, 2 cases were occurred dislocation, and 1 case were died for cardiac disease at 3 months after operation. Four patients were occurred slight pain. There were significant differences in Harris scores among preoperative (41.7±1.4), 6 months after operation(80.1±5.4) and the final follow-up (83.4±2.1), and 10 cases got excellent result, 4 good, 1 fair and 2 poor.
CONCLUSIONSApplication of hip replacement for hip-joint diseases with Parkinson disease is a safe and effective clinical therapy, and has advantages of less complications and rapid recovery of hip joint function.
            

Result Analysis
Print
Save
E-mail